Literature DB >> 3983038

Controversies in the treatment of plasma cell myeloma.

D E Bergsagel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3983038      PMCID： PMC2418142          DOI： 10.1136/pgmj.61.712.109

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  23 in total

Review 1.  Pyrophosphate and diphosphonates in skeletal metabolism. Physiological, clinical and therapeutic aspects.

Authors:  R G Russell; H Fleisch
Journal:  Clin Orthop Relat Res       Date:  1975-05       Impact factor: 4.176

2.  Intermittent high-dose prednisone (NSC-10023) therapy for multiple myeloma.

Authors:  S E Salmon; R K Shadduck; A Schilling
Journal:  Cancer Chemother Rep       Date:  1967-06

3.  Combination chemotherapy for multiple myeloma.

Authors:  R Alexanian; J Bonnet; E Gehan; A Haut; J Hewlett; M Lane; R Monto; H Wilson
Journal:  Cancer       Date:  1972-08       Impact factor: 6.860

4.  Multiple-myeloma bone disease. The comparative effect of sodium fluoride and calcium carbonate or placebo.

Authors:  R A Kyle; J Jowsey; P J Kelly; D R Taves
Journal:  N Engl J Med       Date:  1975-12-25       Impact factor: 91.245

5.  Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone.

Authors:  F Cavagnaro; J M Lein; S Pavlovsky; J O Becherini; J E Pileggi; E Q Micheo; C Jait; A Musso; A Suárez; M Pizzolato
Journal:  Cancer Treat Rep       Date:  1980-01

6.  Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.

Authors:  N Abramson; P Lurie; W L Mietlowski; A Schilling; J M Bennett; J Horton
Journal:  Cancer Treat Rep       Date:  1982-06

7.  The chemotherapy on plasma-cell myeloma and the incidence of acute leukemia.

Authors:  D E Bergsagel; A J Bailey; G R Langley; R N MacDonald; D F White; A B Miller
Journal:  N Engl J Med       Date:  1979-10-04       Impact factor: 91.245

8.  Treatment of plasma cell myeloma with cytotoxic agents.

Authors:  D E Bergsagel; W Pruzanski
Journal:  Arch Intern Med       Date:  1975-01

9.  Unmaintained remissions in multiple myeloma.

Authors:  R Alexanian; E Gehan; A Haut; J Saiki; J Weick
Journal:  Blood       Date:  1978-06       Impact factor: 22.113

10.  Chemotherapy for multiple myeloma.

Authors:  R Alexanian; R Dreicer
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860
View more
  2 in total

1.  A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients.

Authors:  A Belch; W Shelley; D Bergsagel; K Wilson; P Klimo; D White; A Willan
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

2.  Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group.

Authors:  K Shimizu; O Kamiya; N Hamajima; H Mizuno; M Kobayashi; N Hirabayashi; H Takeyama; R Kato; K Kawashima; M Nitta
Journal:  Jpn J Cancer Res       Date:  1990-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.